Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | GLP1R | P43220 | 8/20 | 0.37 |
| ▸ | CA1 | P00915 | 5/20 | 0.37 |
| ▸ | CA12 | O43570 | 4/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | CA4 | P22748 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13616087 | 0.93 | MEN1 (0.53) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL11912094 | 0.90 | MEN1 (0.50) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL21029891 | 0.90 | MEN1 (0.50) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL11912095 | 0.90 | MEN1 (0.50) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL11912086 | 0.88 | ALDH1A1 (0.50) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL24047857 | 0.87 | MEN1 (0.47) | MEN1KMT2AALDH1A1HPGDGLP1R | |
| SCHEMBL21291289 | 0.87 | MEN1 (0.47) | MEN1KMT2AALDH1A1HPGDGLP1R | |
| SCHEMBL19431099 | 0.87 | MEN1 (0.47) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL12019304 | 0.87 | MEN1 (0.47) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL26375472 | 0.87 | MEN1 (0.47) | MEN1KMT2AALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271994-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | UNIV YALE (US) | 2023-08-31 | — | — | US | disclosed |
| WO-2019161213-A1 | TRIALKYNE LINKING AGENTS AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271994-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | MEN1 4199/4885KMT2A 4686/4885ALDH1A1 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.